Enterprise Value
833.4M
Cash
62.51M
Avg Qtr Burn
-10.36M
Short % of Float
4.41%
Insider Ownership
2.50%
Institutional Own.
77.72%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BIVIGAM® Details Autoimmune disease, Immunodeficiency, Primary humoral immunodeficiency | Approved Quarterly sales | |
ASCENIV™ Details Immunodeficiency, Autoimmune disease, Primary humoral immunodeficiency | Approved Quarterly sales | |
Nabi-HB® Details HB (Hepatitis B) | Approved Quarterly sales |